Pirfenidone prevents radiation‐induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF‐&bgr;1/Smad/CTGF signaling pathway

[1]  Jie-shou Li,et al.  Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model. , 2016, Biochemical pharmacology.

[2]  J. Dahlerup,et al.  Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn’s disease , 2016, Scandinavian journal of gastroenterology.

[3]  G. Rogler,et al.  Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis , 2016, Inflammatory bowel diseases.

[4]  L. Morandi,et al.  Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients. , 2016, Life sciences.

[5]  J. Armendáriz-Borunda,et al.  Role and New Insights of Pirfenidone in Fibrotic Diseases , 2015, International journal of medical sciences.

[6]  J. Qi,et al.  Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction. , 2015, Molecular medicine reports.

[7]  Jacob New,et al.  Radiation-induced fibrosis: mechanisms and implications for therapy , 2015, Journal of Cancer Research and Clinical Oncology.

[8]  J. Armendáriz-Borunda,et al.  Pirfenidone prevents rat esophageal stricture formation. , 2015, The Journal of surgical research.

[9]  Don C Rockey,et al.  Fibrosis--a common pathway to organ injury and failure. , 2015, The New England journal of medicine.

[10]  S. Sánchez-Enríquez,et al.  Pirfenidone gel in patients with localized scleroderma: a phase II study , 2014, Arthritis Research & Therapy.

[11]  C. Vancheri,et al.  Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Youn-Hee Choi,et al.  Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy. , 2014, Investigative ophthalmology & visual science.

[13]  T. Kijima,et al.  Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis , 2014, Patient preference and adherence.

[14]  G. Goodall,et al.  Hoxb8 regulates expression of microRNAs to control cell death and differentiation , 2013, Cell Death and Differentiation.

[15]  V. Cottin.  The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis , 2013, Respiratory Research.

[16]  R. Kalluri,et al.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. , 2013, American journal of physiology. Cell physiology.

[17]  F. Rieder,et al.  Cellular and molecular mechanisms of intestinal fibrosis. , 2012, World journal of gastroenterology.

[18]  S. Delanian,et al.  Therapeutic management of intestinal fibrosis induced by radiation therapy: from molecular profiling to new intervention strategies et vice et versa , 2012, Fibrogenesis & tissue repair.

[19]  Chulhee Choi,et al.  Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19 , 2012, Molecular vision.

[20]  R. Swindell,et al.  Gastrointestinal symptoms after pelvic radiotherapy: a national survey of gastroenterologists , 2012, Supportive Care in Cancer.

[21]  Shengshou Hu,et al.  In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion , 2011, PloS one.

[22]  Minbin Yu,et al.  Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. , 2009, Investigative ophthalmology & visual science.

[23]  P. Morel,et al.  Molecular aspects of intestinal radiation-induced fibrosis. , 2009, Current molecular medicine.

[24]  A. Mori,et al.  All-trans-retinoic acid attenuates radiation-induced intestinal fibrosis in mice. , 2008, The Journal of surgical research.

[25]  J. Bourhis,et al.  Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. , 2007, International journal of radiation oncology, biology, physics.

[26]  M. Hauer-Jensen,et al.  Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study. , 2007, World journal of gastroenterology.

[27]  M. Barcellos-Hoff,et al.  A systems biology approach to multicellular and multi-generational radiation responses. , 2006, Mutation research.

[28]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[29]  J. Willis,et al.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.

[30]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[31]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[32]  F. Ridolfi,et al.  Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. , 2002, Journal of hepatology.

[33]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[34]  G. Becker,et al.  Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. , 2001, Journal of nephrology.

[35]  J. Varani,et al.  Rat lung fibroblast collagen metabolism in bleomycin-induced pulmonary fibrosis. , 1985, The Journal of clinical investigation.